GAN & LEE PHARMACEUTICALS. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.57 CNY | -1.08% |
|
-3.82% | -26.74% |
| 09-06 | Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares. | CI |
| 09-05 | Gan & Lee Pharmaceuticals. authorizes a Buyback Plan. | CI |
Projected Income Statement: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,895 | 3,362 | 3,612 | - | 2,608 | 3,511 | 4,458 | 5,419 |
| Change | - | 16.12% | 7.44% | -100% | - | 34.63% | 26.97% | 21.55% |
| EBITDA 1 | - | - | - | - | 537.8 | 921.5 | 1,520 | 1,943 |
| Change | - | - | - | - | - | 71.35% | 64.89% | 27.86% |
| EBIT 1 | - | 1,453 | 1,699 | - | 315.3 | 783.3 | 1,339 | 1,774 |
| Change | - | - | 16.93% | -100% | - | 148.45% | 70.98% | 32.48% |
| Interest Paid | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | 1,445 | 1,696 | - | 306.1 | 778 | 1,337 | 1,772 |
| Change | - | - | 17.33% | -100% | - | 154.13% | 71.85% | 32.54% |
| Net income 1 | - | 1,231 | 1,453 | -439.5 | 340.1 | 690 | 1,153 | 1,543 |
| Change | - | - | 18.04% | - | - | 102.9% | 67.12% | 33.81% |
| Announcement Date | 07/06/20 | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | - | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | -2,439 | -2,317 | -3,092 | -4,076 |
| Change | - | - | - | - | - | -195.01% | -233.45% | -231.82% |
| Announcement Date | 07/06/20 | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | - | - | - |
1CNY in Million
Estimates
Cash Flow Forecast: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| CAPEX 1 | 552.7 | 426 | 255 | 234.5 |
| Change | - | -22.92% | -40.14% | -8.04% |
| Free Cash Flow (FCF) 1 | - | - | - | - |
| Change | - | - | - | - |
| Announcement Date | 24/04/24 | - | - | - |
1CNY in Million
Estimates
Forecast Financial Ratios: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | 20.62% | 26.25% | 34.08% | 35.85% |
| EBIT Margin (%) | - | 43.22% | 47.03% | - | 12.09% | 22.31% | 30.04% | 32.74% |
| EBT Margin (%) | - | 43% | 46.95% | - | 11.74% | 22.16% | 29.99% | 32.7% |
| Net margin (%) | - | 36.61% | 40.22% | - | 13.04% | 19.65% | 25.87% | 28.47% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | - | - | - | 3.05% | 5.23% | 8.62% | 10.34% |
| ROE | - | 17.01% | 15.24% | - | 3.44% | 5.95% | 9.38% | 11.35% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | 21.19% | 12.13% | 5.72% | 4.33% |
| CAPEX / EBITDA (%) | - | - | - | - | 102.77% | 46.23% | 16.78% | 12.07% |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | 2.211 | 1.922 | - | 0.1842 | 1.69 | 2.05 | 2.535 |
| Change | - | - | -13.05% | - | - | 817.48% | 21.3% | 23.66% |
| Dividend per Share 1 | - | - | - | - | 0.2 | 0.16 | 0.195 | 0.23 |
| Change | - | - | - | - | - | -20% | 21.88% | 17.95% |
| Book Value Per Share 1 | - | 15.92 | 18.11 | - | 18.08 | 19.02 | 20.63 | 22.68 |
| Change | - | - | 13.75% | - | - | 5.18% | 8.47% | 9.95% |
| EPS 1 | 2.307 | 2.31 | 2.59 | -0.78 | 0.6 | 1.152 | 1.932 | 2.58 |
| Change | - | 0.12% | 12.12% | -130.12% | -176.92% | 92.08% | 67.68% | 33.51% |
| Nbr of stocks (in thousands) | - | 561,540 | 561,540 | 565,653 | 590,049 | 597,089 | 597,089 | 597,089 |
| Announcement Date | 07/06/20 | 14/04/21 | 27/04/22 | 30/03/23 | 24/04/24 | - | - | - |
1CNY
Estimates
| 2024 * | 2025 * | |
|---|---|---|
| P/E ratio | 33.5x | 20x |
| PBR | 2.03x | 1.87x |
| EV / Sales | 5.9x | 4.47x |
| Yield | 0.41% | 0.51% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
38.57CNY
Average target price
62.00CNY
Spread / Average Target
+60.75%
- Stock Market
- Equities
- 603087 Stock
- Financials Gan & Lee Pharmaceuticals.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition